Plasma proANP1–98 levels are positively associated with central obesity: A cross-sectional study in a general population of China.

Background Atrial natriuretic peptide (ANP) and its prohormone activating enzyme are associated with central obesity, suggesting there may be a potential relationship between proANP 1–98 and central obesity. However, the association is still lack of population-based evidence. We explored the association in a general population of China. Methods We measured plasma proANP 1–98 , waist circumference and other traditional biomarkers in 2203 participants aged ≥ 30 y. Multivariate logistic regression models were used to determine the association between plasma proANP 1–98 and central obesity, and odds ratio (OR) and 95% confidence interval (CI) were calculated. Results High proANP 1–98 was significantly associated with increased risk of central obesity in participants, and the multivariate adjusted OR (95% CI) of central obesity associated with the second, third and fourth quartiles of proANP 1–98 were 1.33 (1.03–1.72), 1.69 (1.31–2.19) and 1.76 (1.35–2.29), respectively, compared with the lowest quartile of proANP 1–98 . There was a dose-response relationship between proANP 1–98 and risk of central obesity among the participants (P trend < 0.001). Sensitivity analyses further confirmed these associations. Adding proANP 1–98 to a model containing conventional risk factors improved discriminatory power of central obesity (as shown by significant improvement in continuous NRI and IDI). Conclusions Contrary to known reduced ANP levels in central obesity, we found that plasma proANP 1–98 was positively associated with central obesity, suggesting that elevated plasma proANP 1–98 may be a marker or a risk factor for central obesity. [ABSTRACT FROM AUTHOR]